Neffy: A Nasal Spray Alternative to EpiPen approved by FDA in the U.S.

FDA approved Epinephrine nasal spray (neffy) for emergency treatment of allergic reaction type 1 in August in adults and pediatric patients who weigh at least 30 kg (or around 66 lbs). Neffy provides an option to treat anaphylaxis that does not involve injection, reducing barrier to treatment. Certain nasal conditions may affect absorption of Neffy such as nasal polyps or history of nasal surgery.

Read more: 

https://www.allergicliving.com/2024/09/23/neffy-epi-sprayers-now-available-in-u-s-pharmacies-and-online/

https://www.aaaai.org/allergist-resources/ask-the-expert/answers/2024/approval

https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214697s000lbl.pdf